What's in DKMS gemeinnützige GmbH's pipeline?

DKMS gemeinnützige GmbH has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with DKMS gemeinnützige GmbH's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dkms-gemeinn-tzige-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

DKMS gemeinnützige GmbH — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DKMS gemeinnützige GmbH pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
HAM	HAM	marketed			Oncology/Hematology
LDAC and/or Mitoxantrone	LDAC and/or Mitoxantrone	phase 3	Chemotherapy combination (nucleoside analog + topoisomerase II inhibitor)	DNA polymerase (cytarabine); Topoisomerase II (mitoxantrone)	Oncology

Therapeutic area mix

Oncology · 1
Oncology/Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for DKMS gemeinnützige GmbH:

Cite this brief

Drug Landscape (2026). DKMS gemeinnützige GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dkms-gemeinn-tzige-gmbh. Accessed 2026-05-16.